Your browser doesn't support javascript.
loading
Effects of Switching from Timolol to Brimonidine in Prostaglandin Analog and Timolol Combination Therapy.
Aihara, Makoto; Adachi, Misato; Hamada, Naoki; Honda, Norihiko; Koseki, Nobuyuki; Matsuo, Hiroshi; Miyata, Kazunori; Otani, Shin-ichiro; Unoki, Kazuhiko.
Afiliación
  • Aihara M; 1 Shirato Eye Clinic , Tokyo, Japan .
  • Adachi M; 2 Eye Rose Clinic , Tokyo, Japan .
  • Hamada N; 3 Omiya Hamada Eye Clinic , Kanagawa, Japan .
  • Honda N; 4 Honda Eye Clinic , Kanagawa, Japan .
  • Koseki N; 5 Koseki Eye Clinic , Saitama, Japan .
  • Matsuo H; 6 Matsuo Eye Clinic , Tokyo, Japan .
  • Miyata K; 7 Miyata Eye Hospital , Miyazaki, Japan .
  • Otani S; 8 Kagoshima Miyata Eye Clinic , Miyazaki, Japan .
  • Unoki K; 9 Unoki Eye Clinic , Kagoshima, Japan .
J Ocul Pharmacol Ther ; 31(8): 482-6, 2015 Oct.
Article en En | MEDLINE | ID: mdl-26114331
PURPOSE: To assess the efficacy and safety of switching from timolol 0.5% to brimonidine 0.1% in patients with glaucoma treated with a prostaglandin analog (PGA) and timolol combination. METHODS: This prospective, open-label multicenter study enrolled patients with open-angle glaucoma or ocular hypertension who were being treated with a PGA and timolol. After baseline measurements, timolol was switched to brimonidine 0.1%, and patients were followed for 12 weeks. Patients visited at 4 and 12 weeks after switching. The main outcome measure was the change in intraocular pressure (IOP). For safety evaluations, hyperemia, formation of conjunctival follicles, superficial punctate keratopathy as a local side effect, blood pressure (BP), and heart rate (HR) were evaluated. RESULTS: One hundred seven patients participated in this study. Among them, 103 patients completed the study. The IOP values at baseline, 4 weeks, and 12 weeks after the transition were 15.7 ± 2.7, 14.3 ± 2.8, and 14.0 ± 2.8 mmHg, respectively. IOP was significantly reduced at 4 and 12 weeks compared with baseline (p<0.001). There were no significant changes in hyperemia or follicle formation. The superficial punctate keratopathy score was significantly reduced at 12 weeks compared with baseline (p<0.05). Systolic and diastolic BP values were significantly reduced and HR significantly increased after switching (p<0.05). CONCLUSION: Switching from timolol 0.5% to brimonidine 0.1% may not change IOP in the combination use of timolol 0.5% and a PGA and was well tolerated by patients without severe ocular or systemic side effects.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Prostaglandinas Sintéticas / Timolol / Glaucoma de Ángulo Abierto / Hipertensión Ocular / Tartrato de Brimonidina / Antihipertensivos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Ocul Pharmacol Ther Asunto de la revista: FARMACOLOGIA / OFTALMOLOGIA / TERAPEUTICA Año: 2015 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Prostaglandinas Sintéticas / Timolol / Glaucoma de Ángulo Abierto / Hipertensión Ocular / Tartrato de Brimonidina / Antihipertensivos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Ocul Pharmacol Ther Asunto de la revista: FARMACOLOGIA / OFTALMOLOGIA / TERAPEUTICA Año: 2015 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos